| Autor: |
Katharina Baur, Dominik Heim, Astrid Beerlage, Anna S Poerings, Bastian Kopp, Michael Medinger, Jan C Dirks, Jakob R Passweg, Andreas Holbro |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Journal for immunotherapy of cancer. 10(12) |
| ISSN: |
2051-1426 |
| Popis: |
Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) are severe, potentially life-threatening side effects of chimeric antigen receptor T-cell (CAR T) therapy caused by the release of cytokines by proliferating and activated CAR T-cells. Current mainstay treatment includes interleukin-1 and interleukin-6 (IL-6) blockade and steroids. The use of steroids is still controversial, since they may have the potential to irreversibly damage CAR T-cells and thus increase the risk of relapse. Therefore, additional treatment options need to be explored. We report the successful treatment of a patient with a grade 3 CRS and grade 4 ICANS refractory to IL-6 blockade and steroids with the tyrosine kinase inhibitor dasatinib. The use of dasatinib for treatment of CAR T-cell therapy-related severe complications warrants further studies. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
